TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31082269

Group type: EXPERIMENTAL
Intervention: NAB-paclitaxel 150 mg/m2 (after study amendment, 125 mg/m2)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: sb-paclitaxel 80 mg/m2
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: NAB-paclitaxel 125 mg/m2
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: NAB-paclitaxel 150 mg/m2
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: NAB-paclitaxel
Number of subjects: 1206

Group type: COMPARATOR
Intervention: sb-paclitaxel
Number of subjects: 1206
Study: 29252150

Group type: EXPERIMENTAL
Intervention: Whey Protein Supplementation (WPS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 26109117

Group type: EXPERIMENTAL
Intervention: Honevo (90% medical‐grade kanuka honey and 10% glycerine)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control cream (Cetomacrogol)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Honevo
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control
Number of subjects: 138
Study: 24359432

Group type: EXPERIMENTAL
Intervention: Intervention 1 (improvements within the current funding model facilitated through an online chronic disease management network)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention 2 (same components as Intervention 1, plus altered funding to support voluntary patient registration, incentive payments, and a care facilitator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study: 21550957

Group type: EXPERIMENTAL
Intervention: SimpleSTEP (insulin aspart added to the largest meal, titration based on premeal glucose values)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: ExtraSTEP (insulin aspart added to the meal with the largest prandial glucose increment, titration based on postmeal glucose values)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Both groups (SimpleSTEP and ExtraSTEP)
Number of subjects: 296
Study: 17928808

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (120 mg elemental iron)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Weekly vitamin A supplementation (25,000 IU)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Iron placebo
Number of subjects: 279
Study: 17095339

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) hydrofluoroalkane 88 mug, twice daily
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo HFA
Number of subjects: 359
Study: 15016259

Group type: EXPERIMENTAL
Intervention: Non-submerged technique (group A)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Submerged technique (group B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 12536544

Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BiPAP) via facial mask
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 0
Study: 9507512

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg dose)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Beta-carotene supplementation and Placebo
Number of subjects: 69
Study: 15552090

Group type: EXPERIMENTAL
Intervention: Uncorrected images
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Corrected images
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal controls (repeated study)
Number of subjects: 63
Study: 2680497

Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Combined treatment (Milrinone + Digoxin)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Milrinone and Digoxin
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Chronic treatment (3 months)
Number of subjects: 230
Study: 1105178

Group type: EXPERIMENTAL
Intervention: Live, attenuated intranasal influenza A vaccine
Number of subjects: 25
Study: 31289983

Group type: EXPERIMENTAL
Intervention: Nomograms for predicting overall survival (OS)
Number of subjects: 6659

Group type: EXPERIMENTAL
Intervention: Nomograms for predicting cancer-specific survival (CSS)
Number of subjects: 6659
Study: 27856633

Group type: EXPERIMENTAL
Intervention: PARI (2 μg/d) with regular sodium diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LS + PARI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LS + PLAC
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LS + PARI (per-protocol analysis)
Number of subjects: 45

Group type: COMPARATOR
Intervention: RS + PLAC
Number of subjects: 45
Study: 25418812

Group type: EXPERIMENTAL
Intervention: KEEP intervention
Number of subjects: 335
Study: 22744545

Group type: EXPERIMENTAL
Intervention: Surgical treatment using the Cotrel-Dubousset method, assessed preoperatively and 12 months postoperatively.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: SRS-22 HRQL instrument used for quality of life assessment post-surgery.
Number of subjects: 87
Study: 20731006

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) interpreted by external experts
Number of subjects: 818

Group type: COMPARATOR
Intervention: Original cytologic interpretation
Number of subjects: 818
Study: 18564391

Group type: EXPERIMENTAL
Intervention: Autologous whole blood (unmodified)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Leukoreduced autologous whole blood
Number of subjects: 1089
Study: 16321914

Group type: EXPERIMENTAL
Intervention: Robotic access
Number of subjects: 304

Group type: COMPARATOR
Intervention: Human access
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Trans‐Atlantic robotic access
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Local robotic access
Number of subjects: 304
Study: 12094254

Group type: EXPERIMENTAL
Intervention: VEGF and VEGFR-2 expression in AML patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VEGF expression in AML patients with high microvessel density
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VEGFR-2 expression in AML patients with high microvessel density
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of VEGF with bone marrow microvessel density
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of VEGFR-2 with bone marrow microvessel density
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VEGFR-2 staining levels post-complete remission
Number of subjects: 32
Study: 10605904

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy in obese patients (Group I)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy in nonobese patients (Group II)
Number of subjects: 145
Study: 8542325

Group type: EXPERIMENTAL
Intervention: Melatonin (0.05 mg, 0.5 mg or 5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1954418

Group type: EXPERIMENTAL
Intervention: Step 1 diet with individual intervention
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Population education
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined population and individual dietary advice
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intensive diets more rigorous than step 2 diet
Number of subjects: 16
Study: 7070696

Group type: EXPERIMENTAL
Intervention: Metoprolol (270 mg/die per os)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Labetalol (270 mg/die per os)
Number of subjects: 20
Study: 31451207

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (200 μg-6 μg Turbuhaler, one inhalation as needed)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Maintenance budesonide (200 μg Turbuhaler, one inhalation twice daily) plus terbutaline (250 μg Turbuhaler, two inhalations as needed)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol
Number of subjects: 885
Study: 28114551

Group type: EXPERIMENTAL
Intervention: Tapering off asthma medications over 4 study visits
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Follow-up after 12 months
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Initial diagnostic workup for asthma in the community
Number of subjects: 701
Study: 26460886

Group type: COMPARATOR
Intervention: Higher-dose edoxaban (HDE, 60 mg/30 mg)
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Lower-dose edoxaban (LDE, 30 mg/15 mg)
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 21105
Study: 25632577

Group type: EXPERIMENTAL
Intervention: Mild moxibustion of Neixiyan (EX-HE4) and Waixiyan (ST 35) for 30 min, once daily for 14 days, followed by moxibustion of Yaoyangguan (GV 3) and Mingmen (GV 4) once daily for next 7 days.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Mild moxibustion of Neixiyan (EX-HE4) and Waixiyan (ST 35) for 30 min, once daily for 14 days (control group).
Number of subjects: 59
Study: 23072406

Group type: EXPERIMENTAL
Intervention: 3D visualization
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2D visualization
Number of subjects: 33
Study: 19546252

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) 0.75 to 1.3 g as a 2‐hour infusion
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg intravenous
Number of subjects: 2
Study: 17069812

Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery occlusion and subsequent minilaparotomy and myomectomy (group I)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Myomectomy alone (group II)
Number of subjects: 82
Study: 16796640

Group type: EXPERIMENTAL
Intervention: Pilocarpine gel 4%
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 3
Study: 14682411

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) levels in exhaled breath condensate of COPD patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) levels in exhaled breath condensate of healthy non-smokers
Number of subjects: 28
Study: 10829583

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Prostaglandins (Iloprost and Alprostadil)
Number of subjects: 96
Study: 8800399

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Supportive living arrangements after hospital discharge
Number of subjects: 28

Group type: COMPARATOR
Intervention: Community discharge
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cocaine dependence
Number of subjects: 28
Study: 1622739

Group type: EXPERIMENTAL
Intervention: Intrasplenic arterial infusion of interleukin-2 (IS-IL-2)
Number of subjects: 18
Study: 6370634

Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 26
Study: 30805949

Group type: EXPERIMENTAL
Intervention: NGM282 1 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: NGM282 3 mg
Number of subjects: 43
Study: 30962251

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with low non-immune-mediated HR (n=61)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with intermediate non-immune-mediated HR (n=52)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with high non-immune-mediated HR (n=24)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with low immune-mediated HR
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with intermediate immune-mediated HR
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI) in individuals with high immune-mediated HR
Number of subjects: 137
Study: 28528859

Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine A (CyA) at 3 mg/kg divided twice daily for 3 months
Number of subjects: 26
Study: 25768026

Group type: EXPERIMENTAL
Intervention: Minimally invasive periventricular device occlusion (MIPDO)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Right subaxillary incision surgical repair (RSISR)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Comparison of MIPDO and RSISR
Number of subjects: 538
Study: 23458037

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2%) and tramadol (2 mg/kg) combination
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sevoflurane (2%) alone
Number of subjects: 34
Study: 21078131

Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressing
Number of subjects: 281

Group type: COMPARATOR
Intervention: Cadexomer iodine dressing
Number of subjects: 281
Study: 18424221

Group type: EXPERIMENTAL
Intervention: Dopaminergic treatment in patients with PD
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Drug-naïve patients with PD
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control subjects (predictable task)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Controls (post-training test)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients (post-training test)
Number of subjects: 37
Study: 16900801

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 80

Group type: COMPARATOR
Intervention: Electrocoagulation
Number of subjects: 80
Study: 15297088

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delayed enteral nutrition (EN)
Number of subjects: 52
Study: 11345755

Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide and oxygen
Number of subjects: 60

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 60
Study: 9218740

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 347

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 347
Study: 7678713

Group type: EXPERIMENTAL
Intervention: Liquid diet
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Semisolid diet
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Breast-fed children
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-breast-fed children
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dietary viscosity (with or without added amylase)
Number of subjects: 56
Study: 3329532

Group type: EXPERIMENTAL
Intervention: 2 mg terbutaline by metered dose inhaler (MDI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline subcutaneously (SC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline placebo SC plus 2 mg terbutaline by MDI
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0.25 mg terbutaline SC plus placebo by MDI
Number of subjects: 9

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 9
Study: 31779791

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder monitoring
Number of subjects: 590
Study: 27997482

Group type: EXPERIMENTAL
Intervention: NIATx intervention
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stepping On
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CDSMP
Number of subjects: 16

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 16
Study: 26138284

Group type: EXPERIMENTAL
Intervention: Program group (educational program)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Text group (textbook reading)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 215
Study: 22782463

Group type: EXPERIMENTAL
Intervention: Capecitabine plus cisplatin (XP)
Number of subjects: 144
Study: 21265818

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rocuronium in patients with baseline Warters scale >3
Number of subjects: 90
Study: 18948612

Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 IU)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16861415

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous midazolam (5 mg)
Number of subjects: 12
Study: 12959636

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aspirin 80 mg/day
Number of subjects: 16
Study: 14676756

Group type: EXPERIMENTAL
Intervention: 2 grams of pheneticillin administered orally one hour before surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administered orally one hour before surgery
Number of subjects: 20
Study: 10967612

Group type: EXPERIMENTAL
Intervention: High-energy breakfast (2920 kJ / 700 kcal)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-energy breakfast (418 kJ / 100 kcal)
Number of subjects: 10
Study: 8864962

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sitostanol ester margarine (3 g/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of pravastatin and sitostanol ester margarine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control margarine (24 g daily)
Number of subjects: 8
Study: 1992960

Group type: EXPERIMENTAL
Intervention: Submaximal exercise test at entry
Number of subjects: 3617

Group type: EXPERIMENTAL
Intervention: Follow-up visit with newly positive test result
Number of subjects: 3617

Group type: EXPERIMENTAL
Intervention: Any positive test result during the study (mean number of tests per subject, 6.2)
Number of subjects: 3617
Study: 6084139

Group type: EXPERIMENTAL
Intervention: Guanabenz (average daily dosage 16 to 31 mg)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ, average daily dosage 50 to 75 mg)
Number of subjects: 147
Study: 31256096

Group type: COMPARATOR
Intervention: Standard Dix-Hallpike test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Dix-Hallpike test with a pillow under shoulders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both tests (Standard and Modified)
Number of subjects: 0
Study: 30001202

Group type: EXPERIMENTAL
Intervention: Adjuvant low-level laser therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (topical medication and compressive therapy)
Number of subjects: 40
Study: 27300579

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily = 100 mg/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg once daily for diet, 50 mg twice daily for metformin = 100 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 24
Study: 25013000

Group type: EXPERIMENTAL
Intervention: Motor control exercises
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 172
Study: 22672148

Group type: EXPERIMENTAL
Intervention: Pharmacist-led education and monitoring programme (n = 23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 46
Study: 20608254

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18073360

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 106
Study: 16138073

Group type: EXPERIMENTAL
Intervention: Amicar (100 mg/kg over 15 minutes, maintenance 10 mg/kg per hour until wound closure)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Amicar (in postoperative suction drainage)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (in postoperative suction drainage)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Amicar (in same-day anterior and posterior spinal surgery)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no Amicar)
Number of subjects: 28
Study: 12103285

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted colectomy (LAC)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 219
Study: 10463091

Group type: EXPERIMENTAL
Intervention: 1.5-hour workshop on breast cyst aspiration (BCA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 69
Study: 7540965

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Placebo (one matching tablet per day)
Number of subjects: 18000
Study: 1975851

Group type: EXPERIMENTAL
Intervention: Budesonide pressurised aerosol 400 micrograms twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 762813

Group type: EXPERIMENTAL
Intervention: Reserpine (0.125 to 0.250 mg) plus Hydroflumethiazide (50 or 100 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Methyldopa (500 to 2,000 mg) plus Hydroflumethiazide (50 or 100 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Propranolol (80 to 320 mg) plus Hydroflumethiazide (50 or 100 mg)
Number of subjects: 59
Study: 29796932

Group type: EXPERIMENTAL
Intervention: Low-phytate wholegrain bread (200 g/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: High-phytate wholegrain bread (200 g/day)
Number of subjects: 102
Study: 27464609

Group type: EXPERIMENTAL
Intervention: Completion lymphadenectomy (CLND)
Number of subjects: 2172

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 2172
Study: 26745689

Group type: EXPERIMENTAL
Intervention: Alcohol brief intervention
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 660
Study: 23986780

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tai Chi plus antihypertensive drugs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 18

Group type: COMPARATOR
Intervention: Antihypertensive drugs
Number of subjects: 18
Study: 21845243

Group type: EXPERIMENTAL
Intervention: MCBS with recombinant human platelet‐derived growth factor BB [rhPDGF‐BB; 0.3 mg/mL]
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MCBS with enamel matrix derivative [EMD]
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of EMD with bone ceramic
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mineral collagen bone substitute [MCBS] scaffold alone
Number of subjects: 16